Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors

BACKGROUND: Immune checkpoint inhibitors that block programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) have improved outcomes for many cancer subtypes but do exhibit toxicity, in the form of immune-related adverse events. OBJECTIVE: The aim of this study was to investigate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Anand, Kartik, Sahu, Geetanjali, Burns, Ethan, Ensor, Allyne, Ensor, Joe, Pingali, Sai Ravi, Subbiah, Vivek, Iyer, Swaminathan P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437685/
https://www.ncbi.nlm.nih.gov/pubmed/32817069
http://dx.doi.org/10.1136/esmoopen-2020-000866

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437685/
https://www.ncbi.nlm.nih.gov/pubmed/32817069
http://dx.doi.org/10.1136/esmoopen-2020-000866

Ejemplares similares